Daniel Kolk, Ph.D., Joins XCR Diagnostics, Inc.

October 18, 2018 |

2 min read

Kolk will be responsible for Clinical Assay Development, Assay Integration and Clinical Trials.

SALT LAKE CITY--(BUSINESS WIRE)-- Daniel Kolk, Ph.D., who has over 20 years of experience in IVD development, joins XCR Diagnostics as the company’s Vice President of Clinical Development. Kolk will be responsible for Clinical Assay Development, Assay Integration and Clinical Trials. His prior experience as Hologic Senior Director Product Development will accelerate XCR Diagnostics’ commercial systems development program. He led the recent development and FDA clearance of multiple respiratory assays on Hologic’s Panther Fusion System. In addition, he previously made major contributions to the development of HPV and blood screening products at Gen-Probe.

“I’m very excited to join XCR Diagnostics, leading their assay development efforts. I look forward to executing and delivering the company’s FDA and CE-IVD clearances of multiple XCR chemistry-based assays,” stated Kolk. “XCR^® chemistry has the ability to alter where, when and how molecular testing is done. Just five years ago one would not have thought about doing molecular testing outside of the central laboratory; however, with this technology I believe we can deliver actionable test results in 10 minutes or less directly to patient, impacting healthcare.”

“XCR Diagnostics has been looking for an action-oriented professional like Dan to accelerate our development efforts,” said Mark Powelson, CEO of XCR Diagnostics. “He has the experience, knowledge and network to take the company through its first FDA Clinical Trial as well as develop the company’s future portfolio of products.”

About XCR Diagnostics, Inc.

XCR Diagnostics, Inc. is an early-stage nucleic acid system company advancing near patient portable molecular diagnostics instrumentation, sample delivery systems, amplification, detection and analysis to the diagnostic markets, domestically and internationally. The company is positioned to provide the first sub-10-minute to a negative test result to the market, meaning a positive result could be as rapid as 7 minutes. The combination of small, portable Nucleic Acid Testing Systems (pNATS™) platforms and revolutionary molecular reagents enables XCR Diagnostics to dramatically trim test times and reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing near patient and central laboratory. To learn more about XCR Diagnostics, please visit us at www.xcrdiagnostics.com.